– First to offer suite of tests in easy to access
format for children with developmental disabilities –
SAN
FRANCISCO, April 4, 2022 /PRNewswire/ -- Invitae
(NYSE: NVTA), a leading medical genetics company, today announced
the full commercial launch of its Neurodevelopmental Disorders
(NDD) package to deliver a robust testing suite that can deliver
actionable genetic insights to inform treatment plans for children
with developmental disabilities. Invitae is the first to offer this
particular suite of tests to clinicians and patients in an easily
accessible format.
The package includes chromosomal microarray analysis, analysis
for fragile X-related disorders, and a next-generation-sequencing
panel of 200+ genes in which variants are associated with
neurodevelopmental disorders. The gene panel can detect sequence
variants as well as full or partial gene deletions and duplications
(i.e. intragenic copy number variants) that a chromosomal
microarray analysis (CMA) alone may not detect. The comprehensive
package provides reports for all three tests and can help provide
clarity on the genetic etiology and root cause of these complex and
sometimes overlapping conditions. The package is accessible,
affordable, and fast, with test results delivered in 10-21
days.
"The NDD package provides genetic answers in a timely fashion,
with a goal of informing physicians and parents, informing care
decisions and developing appropriate treatment plans for patients,"
said Robert Nussbaum, M.D., chief
medical officer, Invitae. "Although numerous other labs offer each
individual component, Invitae is the only lab to offer this as a
comprehensive suite of tests with rapid turn-around time of 10-21
days. We make it easy to access the entire suite of tests by
providing one dedicated sample collection kit."
One in six children between the ages of 3 and 17 years old has a
developmental disability, yet two out of three children do not
receive the recommended genetic testing. The NDD package is
supported by guidelines from the American Academy of Pediatrics
that recommend CMA and fragile X syndrome testing for children with
intellectual disability, global developmental delay, or autism
spectrum disorder. They also recommend further testing that may
include gene panels and whole exome sequencing.
To learn more about the Invitae NDD package, visit Invitae.
About Invitae
Invitae Corporation (NYSE: NVTA) is a
leading medical genetics company, whose mission is to bring
comprehensive genetic information into mainstream medicine to
improve healthcare for billions of people. Invitae's goal is to
aggregate the world's genetic tests into a single service with
higher quality, faster turnaround time and lower prices. For more
information, visit the company's website at invitae.com.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the availability, features and potential impact of the
company's products; the company's belief that it is the first and
only laboratory to offer this comprehensive suite of tests for
neurodevelopmental disorders in an easily accessible format; the
company's belief that its NDD package is affordable and fast; and
the company's belief that its NDD package will inform care
decisions and treatment plans for patients. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially, and reported results should
not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: the
company's history of losses; the company's ability to compete; the
company's failure to manage growth effectively; the company's need
to scale its infrastructure in advance of demand for its tests and
to increase demand for its tests; the company's ability to use
rapidly changing genetic data to interpret test results accurately
and consistently; security breaches, loss of data and other
disruptions; laws and regulations applicable to the company's
business; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Annual Report on Form 10-K for the year
ended December 31, 2021. These
forward-looking statements speak only as of the date hereof, and
Invitae Corporation disclaims any obligation to update these
forward-looking statements.
- Zablotsky B, et al. Pediatrics. 2019;144(4):e20190811. doi:
10.1542/peds.2019-0811
- Kiely B, et al. Appl Clin Genet. 2016;9:93–100. doi:
10.2147/TACG.S103975
- Lipkin PH, Macias MM. Pediatrics. 2020;145(1):e20193449. doi:
10.1542/peds.2019-3449
Contact:
pr@invitae.com
(628) 213-3283
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invitae-introduces-first-comprehensive-genetic-test-suite-for-neurodevelopmental-disorders-301516255.html
SOURCE Invitae Corporation